Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesProstate cancer chemoprevention: What's the next step
Urology Times, 06/22/09
Thrasher JB - The data provide strong evidence that hormonal manipulation with 5-ARIs reduces the relative risk of prostate cancer, but multiple questions remain. Further analysis of the REDUCE trial with longer follow-up and pathologic analysis will help us answer these questions and direct therapy.
Related Articles
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Relevance Score: 72%
Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection
The Journal of Urology, 11/13/09
Relevance Score: 71%
A prospective study of lifetime physical activity and prostate cancer incidence and mortality
British Journal of Cancer, 11/02/09
Relevance Score: 71%
Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men
The Prostate, 11/02/09
Relevance Score: 71%
Prostate specific antigen for early detection of prostate cancer: longitudinal study
British Medical Journal, 10/08/09
Relevance Score: 71%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)
Annals of Oncology, 12/04/09
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Annals of Oncology, 12/04/09
Three-dimensional (3D) Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to MEK Inhibitors
Journal of Pharmacology and Experimental Therapeutics, 12/04/09
Sponsor
Article Search
Sponsor